Diffusion Pharmaceuticals Inc. DFFN Income Statement

Diffusion pharmaceuticals inc. (DFFN)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Sep'11	Jun'11	Sep'10	Jun'10
Events
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Licensing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	215	374	0	0	0	0	0	-	0
Cost of revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	235	484	483	0	0	0	-	0
Gross margin
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	207	138	212	69	0	0	0	-	0
Operating expenses:
Research and development
6,454	6,619	6,327	5,753	5,626	5,751	5,528	6,118	5,906	5,088	5,459	5,641	5,907	7,252	7,012	5,992	5,496	3,875	3,754	4,105	3,423	2,860	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
5,027	4,834	4,978	5,277	5,870	6,167	6,031	6,001	6,136	6,191	5,938	8,231	8,784	11,094	11,358	7,928	5,926	2,522	1,896	3,344	4,208	4,760	9,836	8,414	7,717	7,331	2,583	3,190	3,732	4,570	6,125	6,189	0	0	0	0	0
Goodwill impairment
-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation
106	97	99	108	100	110	109	110	89	67	45	24	24	25	21	18	14	8	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of other intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-
Impairment of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	-	-	-
Warrants, options and stock compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,876	5,121	4,719	3,643	0	0	0	0	0	0	0
Fair value of common stock exchanged for warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-
Fair value of common stock exchanged for warrants and notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Legal and professional services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,711	1,563	1,701	2,128	2,659	2,772	0	0	0	0	0
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	566	976	615	299	116	158	160	162	164	51	54	0	0	0	0	0
Former employee severance expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
TOTAL EXPENSES
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14,613	7,627	5,779	12,075	12,796	14,363	16,268	11,740	11,930	13,557	12,045	0	0	0	0	0
Loss from operations
-11,588	-11,551	-14,148	-18,068	-18,526	-18,958	-15,855	-12,229	-12,132	-11,348	-11,443	-13,897	-14,715	-18,371	-18,392	-13,938	-11,436	-6,406	-11,765	-13,931	-14,434	-14,613	-7,627	-5,779	-12,075	-12,796	-14,440	-16,203	-11,532	-11,791	-13,344	-11,975	0	0	0	0	0
Other income:
Interest income
98	85	90	106	134	151	146	109	45	-48	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on adjustments to fair value of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,980	6,957	0	0	-	-	0	-	-	-	-	-
Gain on extinguishment of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-
Loss on settlement of notes payable - related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on settlement of notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Other (income) expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	-634	-588	-608	-660	-104	0	0	-	-	0	-	-	-	-	-
Interest expense, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	235	262	313	152	162	266	273	382	309	207	126	-26	0	0	-	-	0	-	-	-	-	-
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-22,072	-18,909	-10,468	12,919	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant related expenses
-	-	-	-	-	-	-	-	-	10,225	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant related expenses (Note 7)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Gain)/loss on adjustments to fair value of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Other financing expenses
-	-	-	-	-	-	-	-	-	2,870	2,870	2,870	2,870	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0
TOTAL OTHER (INCOME)/EXPENSES
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,555	-3,970	-3,850	9,563	9,828	6,022	5,948	-6,729	-4,942	-293	-343	0	0	0	0	0
Loss from operations before income tax benefit
-11,489	-11,466	-14,058	-17,962	-18,391	-18,807	0	0	0	-	0	0	-	-	0	-	-	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax benefit
120	332	-699	-741	0	-	0	0	-	-	0	0	-	-	0	-	-	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributed to non-controlling interests
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	0	0	0	-	-	-	-
Net loss
-11,610	-11,799	-13,618	-17,533	-17,803	-18,369	-11,009	807	23,960	-1,364	-5,724	-16,258	-40,452	-18,036	-18,187	-14,173	-11,698	-6,719	0	0	0	-	-	-	-	-	-	-	-	-6,868	-9,413	-8,094	0	0	0	0	0
Accretion of Series A cumulative preferred dividends
-	-	-	-	-	85	425	792	1,279	1,252	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Undistributed earnings to participating securities
-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock
-	-	-	-	-	8,167	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LOSS FROM CONTINUING OPERATIONS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,967	0	0	0	-	-	-	-	-	-	-	-
Income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	503	0	0	0	-	-	-	-	-	-	-	-
NET LOSS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,464	14,293	-5,349	-9,019	-6,849	0	0	0	-	-	-	-
Preferred dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Preferred dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124,375.00	131,750.00	121,505.00	119,744.00	124,168.00	-	-	-	-
Net loss attributable to common stockholders
-	-	-13,618	-17,533	-	-26,623	-17,764	-8,152	14,512	-2,616	0	0	0	-	-	-	0	-	-	-	-	-14,352	-10,094	-8,170	-1,414	-2,635	13,964	-5,810	-9,552	-7,366	0	0	0	-	-	-	-
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)
-0.07	0.28	-0.60	-0.63	-0.81	-1.29	-1.99	-0.82	-4.11	-	0.21	0.88	-	-	-0.53	-0.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding, basic and diluted (in dollars per share)
34,507,496.00	-5,303,695.00	4,693,290.00	3,940,684.00	3,376,230.00	-6,313,253.00	3,371,468.00	3,369,770.00	2,814,316.00	-	0.20	-1.00	-	-	-0.53	-0.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic and diluted loss per share for continuing operations - attributable to RestorGenex Corporation (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.10	-0.39	0.87	-2.77	-	-	-	-	-	-	-	-
Basic and diluted income per share for discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.36	0.02	-0.05	-0.14	-	-	-	-	-	-	-	-
Net loss per share of common stock, basic and diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-2.78	-	-	-	-0.62	-1.80	-0.64	-0.06	-0.06	-0.24	-0.18	-0.35	-0.23	1.46	-0.37	0.82	-2.91	-8.10	-0.04	-0.02	0.00	-0.06	-0.03	-0.03	-0.03
Weighted average shares outstanding, basic and diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	10,337	-	-	-	9,996	-35,917	2,222	22,087	22,087	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average shares outstanding, basic (in shares)
-	-	-	-	-	-	-	-	-	-	13,937	10,828	-	-	10,333	10,263	-	-	-	-	-	19,724	18,671	12,867	5,934	-	-	-	-	-	89,748	-	-	77,535	71,161	62,522	60,768
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,687	4,144	2,862	892	-264,048	89,755	89,748	88,157	-	-	-	-
Weighted average shares outstanding, diluted (in shares)
-	-	-	-	-	-	-	-	-	-	14,714	13,872	-	-	10,333	10,263	-	-	-	-	-	19,724	18,671	12,867	5,934	2,372	4,144	2,862	1,207	-347,672	124,838	117,915	109,407	-	-	-	-